Flexion Therapeutics

208 articles about Flexion Therapeutics

• Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

  5/12/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2021.

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021

  5/7/2021

  Flexion Therapeutics, Inc. announced equity inducement grants to eight new employees consisting of 18,200 restricted stock units.

• Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021

  5/5/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021.

• Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

  4/28/2021

  Findings from a Phase 1 single ascending dose trial indicate the low dose of FX201, an intra-articular gene therapy candidate for osteoarthritis (OA), was generally well-tolerated Two of five patients (40%) treated with FX201 in the low-dose, single ascending dose cohort reported substantial improvement in pain out to Week 24 No evidence of systemic biodistribution of FX201 in plasma or shedding in urine or at the injection site was observed in any patient

• Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021

  4/13/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of approximately $24.6 million for the quarter ended March 31, 2021.

• Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference

  4/8/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20 th Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 9:30 a.m. ET on Thursday, April 15, 2021. To access the live webcast of the presentation, please visit the Flexion website at  http://ir.flexiontherapeutics.com . A

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 02, 2021

  4/2/2021

  Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of 60,880 restricted stock units.

• Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain

  3/31/2021

  FX301 is a locally administered NaV1.7 inhibitor (funapide) formulated for extended release in a proprietary thermosensitive hydrogel Proof-of-concept trial will evaluate safety and tolerability of FX301 administered as a peripheral analgesic nerve block in patients undergoing bunionectomy; initial data anticipated later this year

• Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference

  3/15/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference

• Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results

  3/10/2021

  Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021

  3/5/2021

  Flexion Therapeutics, Inc. announced equity inducement grants to four new employees consisting of 14,565 restricted stock units.

• Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021

  3/3/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021.

• Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain

  3/1/2021

  FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while preserving motor function following musculoskeletal surgery

• Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference

  2/22/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 nd Annual Raymond James Institutional Investors Conference. The virtual fireside chat is scheduled to begin at 12:30 p.m. ET on Monday, March 1, 2021.

• Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups

  2/18/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced plans to advance FX201 into the high dose cohort of the Phase 1 dose-escalation trial.

• 

  BioSpace Movers & Shakers, Jan. 29

  1/29/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results

  1/13/2021

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020.

• Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

  1/7/2021

  - Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fireside chat is scheduled to begin at 10:45 a.m. ET on Thursday, January 14, 2021. To access the live webcast of the presentation, please visit the Flexion website at  http://ir.flexiontherapeutics.com . About

• Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

  12/7/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  Flexion Therapeutics, Inc. announced equity inducement grants to six new employees consisting of 22,798 restricted stock units.